Efficacy and safety of nitazoxanide plus atazanavir/ritonavir for the treatment of moderate to severe COVID-19 (NACOVID): A structured summary of a study protocol for a randomised controlled trial

Peer Review reports

Original Submission
14 Dec 2020	Submitted	Original manuscript
17 Dec 2020	Reviewed	Reviewer Report - Kirsty Loudon
Resubmission - Version 2
	Submitted	Manuscript version 2
Publishing
18 Dec 2020	Editorially accepted
4 Jan 2021	Article published	10.1186/s13063-020-04987-8

Back to article page